ClinicalTrials.gg
RecruitingNCT07159204PILOT-BTCUpdated Oct 15, 2026

Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer

A Phase 2 interventional study of Paclitaxel polymer micelle immunocombination in Biliary Tract Cancer (BTC), sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2024, registered Aug 2025).
  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Biliary Tract Neoplasms by Peking Union Medical College Hospital — 11 open to participants now, 12 under way, none of them phase 3. Biliary Tract Neoplasms · Peking Union Medical College Hospital.

Planned enrollment
13th of 14
25 · median 60
Started
2024
with 2 others
Phase 2
13 of 16
10 open now
Primary completion
2027-08
later than 10 of 11 live
Registered
11th of 16
by date

Among the 16 studies in Biliary Tract Neoplasms by Peking Union Medical College Hospital, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 10 of the 11 other live ones, and was the 11th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

11 of the 16 studies in Biliary Tract Neoplasms by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Biliary Tract Neoplasms by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen

03

Conditions studied

  • Biliary Tract Cancer (BTC)
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily participated in the study, provided written , and were willing to comply with study treatment, assessments, and follow-up. Patients were ≥18 years old and \<75 years old at the time of signing informed consent, regardless of gender.
  • Patients with advanced biliary tract carcinoma diagnosed by imaging and histology as unresectable, recurrent, locally advanced, or disease, defined as stage IIIA or above according to the AJCC 8th edition staging system, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer. No more than two metastatic organ sites were allowed, including liver, lung, bone, and brain.
  • Radical surgery or local treatment, including focal excision, ablation, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and radiotherapy, was not appropriate, or disease progression occurred after local treatment. At least 4 weeks should have elapsed after local treatment before baseline assessment, and acute toxicities related to prior treatment should have recovered to version 5.0 grade 1 or lower.
  • Patients had disease progression after, or intolerance to, systemic therapy for at least 1 month and required subsequent palliative systemic treatment. Treatment-related adverse events should have recovered to NCI-CTCAE version 5.0 grade 1 or lower before enrollment.
  • At least one according to version 1.1 (a measurable lesion with a longest diameter ≥10 mm by CT/MRI or an enlarged lymph node with a short-axis diameter ≥15 mm).
  • performance status was 0-1 within 1 week before enrollment, and expected survival was ≥3 months as assessed by investigators.
  • Active or patients were required to receive antiviral therapy. HBV DNA should be \<2,000 IU/mL (\<10⁴ copies/mL), and anti-HBV therapy should have been administered for at least 14 days before study entry and continued during treatment. HCV RNA-positive patients should receive antiviral therapy according to local standard treatment guidelines, with liver function abnormality no higher than CTCAE grade 1.
  • Hematologic and organ function were adequate based on laboratory results obtained within 14 days prior to initiation of therapy.
  • Any biliary obstruction should have been resolved before enrollment.
  • Adequate renal function: serum creatinine ≤1.5× or >50 mL/min.
  • Women of agreed to abstain from sexual intercourse or use highly effective with an annual failure rate of \<1% during treatment and for at least 6 months after the last dose.
  • Male participants agreed to abstain from sexual intercourse or use appropriate contraception and agreed not to donate sperm.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with polymeric micellar paclitaxel or its analogues, or known or intolerance to polymeric micellar paclitaxel, paclitaxel or its components, lenvatinib, or the planned .
  • Histopathological results showing combined hepatocellular-cholangiocarcinoma, squamous cell carcinoma, sarcoma components, or ampullary carcinoma.
  • Patients with other active or other incompletely treated malignant tumors within the previous 5 years.
  • Significant digestive tract diseases, including grade ≥3 digestive tract fistula or non-digestive tract fistula according to version 5.0, history of gastrointestinal bleeding within the previous 6 months, clear gastrointestinal bleeding tendency, or grade ≥3 gastrointestinal bleeding events.
  • cardiovascular and cerebrovascular diseases, including acute myocardial infarction, severe or unstable angina, cerebrovascular accident, within 6 months before enrollment, clinically significant heart failure, arrhythmia requiring treatment, uncontrolled hypertension despite antihypertensive therapy, or thromboembolic events within the previous 6 months.
  • Severe hepatic or renal dysfunction, including jaundice, ascites, or >3×; renal failure requiring dialysis; or clinically significant proteinuria. Patients who received strong inhibitors within 7 days or strong CYP3A4 inducers within 12 days before study treatment were also excluded.
  • Active, known, or suspected diseases requiring systemic treatment, or history of organ transplantation or bone marrow transplantation. Patients with type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, or skin diseases not requiring systemic treatment were allowed if clinically appropriate.
  • Untreated or active central nervous system , , or epilepsy requiring medical treatment. Patients with previously treated and stable could participate if imaging showed no progression for at least 4 weeks before treatment initiation, neurological symptoms returned to baseline, and were not required for at least 7 days before treatment.
  • Persistent infection of CTCAE grade >2, known active tuberculosis, or known infection.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Paclitaxel polymer micelle immunocombination

    Drug: Paclitaxel polymer micelle immunocombination

Interventions

  • DrugPaclitaxel polymer micelle immunocombination

    Paclitaxel polymer micelle immunocombination

This study also gives LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Proportion of participants with a best overall response of complete response or partial response according to RECIST version 1.1, as assessed by investigators. Tumor assessments were performed at baseline, every two treatment cycles during induction (each treatment cycle was 21 days), and approximately every 6-9 weeks during maintenance.

    Time frame: From baseline until the earliest of documented disease progression, initiation of new anticancer therapy, or the primary outcome data cutoff, assessed up to 24 months.

Secondary outcomes

  1. Disease control rate

    Proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST version 1.1, as assessed by investigators. Tumor assessments were performed at baseline, every two treatment cycles during induction (each treatment cycle was 21 days), and approximately every 6-9 weeks during maintenance.

    Time frame: From baseline until the earliest of documented disease progression, initiation of new anticancer therapy, or the tumor response data cutoff, assessed up to 24 months.

  2. Progression-Free Survival (PFS)

    Progression-free survival was defined as the time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurred first.

    Time frame: From the first dose of study treatment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurred first, assessed up to 36 months.

  3. Overall Survival (OS)

    Overall survival was defined as the time from the first dose of study treatment to death from any cause.

    Time frame: From the first dose of study treatment to death from any cause, assessed up to 36 months.

  4. Safety and Tolerability

    The incidence, type, and severity of adverse events, treatment-related adverse events, serious adverse events, and clinically significant abnormalities in laboratory test results and vital signs. Adverse events were graded according to NCI CTCAE version 5.0.

    Time frame: From signing informed consent through 28 days after the last dose of study treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kim JY, Do YR, Song HS, Cho YY, Ryoo HM, Bae SH, Kim JG, Chae YS, Kang BW, Baek JH, Kim MK, Lee KH, Park K. Multicenter Phase II Clinical Trial of Genexol-PM(R) with Gemcitabine in Advanced Biliary Tract Cancer. Anticancer Res. 2017 Mar;37(3):1467-1473. doi: 10.21873/anticanres.11471. PubMed 28314319 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2027, 36 months after the start.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 36 months is close to that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Aug 2026 → Aug 2027 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 8, 2025
StartActual
Aug 7, 2024
Primary completionEst.
Aug 7, 2027was Aug 2026
CompletionEst.
Dec 7, 2028was Dec 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 15, 2026
Sites
Peking Union Medical College Hospital is now Recruiting
Oct 15, 2026
Primary completion
Aug 12, 2026→Aug 7, 2027
Oct 15, 2026
Study completion
Dec 7, 2027→Dec 7, 2028
Oct 15, 2026
Enrollment
61 (actual)→25 (estimated)
Oct 15, 2026
Contact
Study contact now listed: added j•••@163.com · •••2188. See the current contact
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Peking Union Medical College Hospital · Beijing, ChinaContact added p•••@126.com · •••8182
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Recruiting
    Peking Union Medical College Hospital is now Recruiting
    Primary completion Aug 12, 2026→Aug 7, 2027
    Study completion Dec 7, 2027→Dec 7, 2028
    Enrollment 61 (actual)→25 (estimated)
    Contact Study contact now listed: added j•••@163.com · •••2188. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Peking Union Medical College Hospital · Beijing, ChinaContact added p•••@126.com · •••8182

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07159204
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 7, 2024
Primary completion
Aug 7, 2027 (estimated)
Completion
Dec 7, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Jiongyuan Li
Contact
jypeking@163.com
010-69152188

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion